GT Biopharma Enters Agreement for $7.45 Million Private Placement Financing

GT Biopharma, Inc. has entered into a Securities Purchase Agreement for a private placement of convertible preferred stock and warrants, raising an aggregate of $7.45 million. The agreement also provides purchasers with a greenshoe option to purchase up to an additional $30 million in securities.

Key Details

• Financing Terms: The company will issue up to 8,277.778 shares of its Series M 10% Convertible Preferred Stock and accompanying warrants for a total purchase price of $7.45 million, as disclosed on September 14, 2026.
• Conversion & Exercise Price: The Preferred Stock is convertible into common stock at an initial price of $6.10 per share. The issued warrants have an initial exercise price of $6.10 per share and a five-year term.
• Greenshoe Option: Purchasers have the right to purchase additional preferred stock with an aggregate stated value of up to $33.3 million for an aggregate purchase price of $30.0 million.